Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Novartis (Mid-Stage Clinical Product Portfolio)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Novel products for the treatment of diseases with unmet medical need. It includes human monoclonal antibody to improve bone density in osteogenesis imperfecta (OI), an orally active aromatase inhibitor for the treatment of obese men with hypogonadotrophic hypogonadism and a orally active p38 MAP kinase inhibitor for the treatment and supportive care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Primary Office
  • Basel
  • Switzerland

Novartis (Mid-Stage Clinical Product Portfolio) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Novartis (Mid-Stage Clinical Product Portfolio)‘s full profile, request access.

Request full access to PitchBook

Novartis (Mid-Stage Clinical Product Portfolio) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Novartis (Mid-Stage Clinical Product Portfolio)‘s full profile, request access.

Request full access to PitchBook